相关实验视频

Updated: May 9, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

1.9K

深度神经网络基础竞争风险在预测心力衰竭患者的存活率

Solmaz Norouzi1, Ebrahim Hajizadeh1, Mohammad Asghari Jafarabadi2,3

  • 1Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Journal of diabetes and metabolic disorders
|May 2, 2025
PubMed
概括

深度神经网络竞争风险 (DNNCR) 模型比随机生存森林 (RSF) 模型更好地预测心力衰竭 (HF) 患者的生存结果. 这种人工智能方法有助于识别高风险个体,以定制治疗策略.

关键词:
竞争的风险 竞争的风险深度神经网络是一个神经网络.心脏衰竭是因为心脏衰竭.预测 预测 预测幸存的生存方式

更多相关视频

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

6.6K
Establishing a Competing Risk Regression Nomogram Model for Survival Data04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.0K

相关概念视频

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
259